Lung cancer is the number one cause of cancer death in the United States, expected to cause 158,000 deaths in 2016, and accounting for 26.5% of all cancer deaths. It is the second most common cancer in both men (after prostate cancer) and women (after breast cancer), with 118,000 and 106,000 new cases expected in 2016, respectively. Lung cancer includes different pathological types, broadly divided into small-cell lung cancer and non-small-cell lung cancer (NSCLC). NSCLC makes up about 85% of lung cancers and comprises mainly squamous cell carcinoma, adenocarcinoma, and large-cell lung cancer. Stage at diagnosis is a primary factor in patient survival, and patients with NSCLC commonly present with advanced disease.

For questions or additional information, please contact info@icer.org

Interventions of Interest:

  • Tyrosine kinase inhibitors:
  • Afatinib (Gilotrif®, Boehringer Ingelheim Pharmaceuticals, Inc.)
  • Erlotinib (Tarceva®, Genentech, Inc. and Astellas Pharma US, Inc.)
  • Gefitinib (Iressa®, AstraZeneca)
  • Immunotherapies targeting the programmed death 1 (PD-1) receptor or its ligand (PD-L1):
  • Atezolizumab (Tecentriq®, Genentech, Inc., Roche Group)
  • Nivolumab (Opdivo®, Bristol-Meyers Squibb Co.)
  • Pembrolizumab (Keytruda®, Merck & Co.)

Final Documents

Below you will find the final documents from the assessment review process: